Abstract: An electric field stirring apparatus, in which a droplet as a liquid disposed between a first electrode and a second electrode disposed to face each other is vibrated and stirred by an electric field generated between the first electrode and the second electrode, the second electrode having a groove formed along a first direction on an electrode surface facing the first electrode, includes a movement mechanism that reciprocally moves the first electrode relative to the second electrode in a second direction intersecting the first direction in a state in which the first electrode and the second electrode face each other during a period in which the electric field is generated.

Abstract: A pathological specimen preparation device includes a stage portion including a stage, a reagent supply portion 150 capable of supplying a reagent to a substrate W mounted on the stage, a washing portion capable of supplying a washing solution to the substrate, an electric field stirring portion capable of stirring the reagent or the washing solution supplied to the substrate by applying an electric field to the reagent or the washing solution, and a control unit, wherein the washing portion, the reagent supply portion, and the electric field stirring portion are sequentially disposed in a Y direction as a first direction, and the device includes a stage transport mechanism that moves the stage in the Y direction, and a stage tilting mechanism that tilts the stage in an X direction as a second direction crossing the Y direction when the stage is positioned in the washing portion.

Abstract: A reagent cartridge includes a drug solution storage section which has a first window section and a drug solution chamber, a case section which holds the drug solution storage section movably in the negative Z-axis direction and has a second window section and a nozzle section, a spring which biases the drug solution storage section, and a discharge mechanism for discharging a predetermined amount of the drug solution from the nozzle section by the moving motion of the drug solution storage section within a predetermined range.

Abstract: An electric field stirring apparatus, in which a droplet as a liquid disposed between a first electrode and a second electrode disposed to face each other is vibrated and stirred by an electric field generated between the first electrode and the second electrode, the second electrode having a groove formed along a first direction on an electrode surface facing the first electrode, includes a movement mechanism that reciprocally moves the first electrode relative to the second electrode in a second direction intersecting the first direction in a state in which the first electrode and the second electrode face each other during a period in which the electric field is generated.

Abstract: A pathological specimen preparation device includes a stage portion including a stage, a reagent supply portion 150 capable of supplying a reagent to a substrate W mounted on the stage, a washing portion capable of supplying a washing solution to the substrate, an electric field stirring portion capable of stirring the reagent or the washing solution supplied to the substrate by applying an electric field to the reagent or the washing solution, and a control unit, wherein the washing portion, the reagent supply portion, and the electric field stirring portion are sequentially disposed in a Y direction as a first direction, and the device includes a stage transport mechanism that moves the stage in the Y direction, and a stage tilting mechanism that tilts the stage in an X direction as a second direction crossing the Y direction when the stage is positioned in the washing portion.

Abstract: A reagent cartridge includes a drug solution storage section which has a first window section and a drug solution chamber, a case section which holds the drug solution storage section movably in the negative Z-axis direction and has a second window section and a nozzle section, a spring which biases the drug solution storage section, and a discharge mechanism for discharging a predetermined amount of the drug solution from the nozzle section by the moving motion of the drug solution storage section within a predetermined range.

Abstract: A PCR device, in which a vessel is filled with a liquid which has a lower specific gravity than a reaction mixture and is immiscible with the reaction mixture, and a control section drives and controls a first heating section and a second heating section so that the liquid in an upper part in the vessel is brought to a first temperature and the liquid in a lower part is brought to a second temperature which is lower than the first temperature, and also drives and controls an electric field generation section to generate an electric field between a lower electrode and an upper electrode so that the reaction mixture in a spherical shape in the liquid moves up and down repeatedly between the upper part and the lower part of the liquid by a Coulomb force due to the electric field.

Abstract: A droplet oscillation device includes upper and lower electrodes, a changing mechanism, a sensor and a controller. The lower electrode is configured to support a substrate thereon. The changing mechanism is configured to change a distance between the upper and lower electrodes. The sensor is configured to detect a droplet formed above a surface of the substrate opposite the upper electrode. The controller is configured to vary an applied voltage between the upper and lower electrodes to oscillate the droplet, and to determine whether the droplet is detected by the sensor. The controller is configured to respectively determine whether the droplet is detected under a plurality of conditions for which a frequency of the applied voltage or the distance are different, and to oscillate the droplet at the frequency and the distance of a condition for which the droplet is detected and for which the distance is greatest.

Abstract: The present invention relates to hypotriglyceridemic agent containing HMG-CoA reductase inhibitor and cAMP protease inhibitor.

Abstract: A droplet oscillation device includes upper and lower electrodes, a changing mechanism, a sensor and a controller. The lower electrode is configured to support a substrate thereon. The changing mechanism is configured to change a distance between the upper and lower electrodes. The sensor is configured to detect a droplet formed above a surface of the substrate opposite the upper electrode. The controller is configured to vary an applied voltage between the upper and lower electrodes to oscillate the droplet, and to determine whether the droplet is detected by the sensor. The controller is configured to respectively determine whether the droplet is detected under a plurality of conditions for which a frequency of the applied voltage or the distance are different, and to oscillate the droplet at the frequency and the distance of a condition for which the droplet is detected and for which the distance is greatest.

Abstract: The present invention provides a method for treatment of diabetes, comprising administering a pitavastatin, and in combination therewith, enalapril or a salt thereof.

Abstract: The present invention is directed to a triglyceride-lowering agent, exhibiting excellent triglyceride-lowering effect and a hyperinsulinemia-ameliorating agent. The triglyceride-lowering agent and hyperinsulinemia-ameliorating agent are characterized by containing a pitavastatin compound, and amlodipine or a salt thereof.

Abstract: The present invention is directed to a triglyceride-lowering agent, exhibiting excellent triglyceride-lowering effect and a hyperinsulinemia-ameliorating agent. The triglyceride-lowering agent and hyperinsulinemia-ameliorating agent are characterized by containing a pitavastatin compound, and amlodipine or a salt thereof.

Abstract: The present invention is directed to a triglyceride-lowering agent, exhibiting excellent triglyceride-lowering effect and a hyperinsulinemia-ameliorating agent. The triglyceride-lowering agent and hyperinsulinemia-ameliorating agent are characterized by containing a pitavastatin compound, and amlodipine or a salt thereof.

Abstract: A compound represented by the following general formula (I), wherein R1, R2, R3, R4 and R5 represent hydrogen atom, a halogen atom, a lower alkyl group and the like, R6 represents an alkyl group, a cycloalkyl group and the like, R7 and R8 represent hydrogen atom, a lower alkyl group, a (lower cycloalkyl)(lower alkyl) group and the like, R9 represents hydrogen atom, a halogen atom, a lower alkoxy group and the like, R10 and R11 represent hydrogen atom, a lower alkyl group, a lower alkoxy group, a halo(lower alkyl) group and the like, and A represents a heterocyclic ring constituted by 6 to 10 atoms, which has potent inhibitory activity on cholesterol ester transfer protein (CETP).

Abstract: The present invention provides a communication device and a communication method of an underwater vehicle, which use an electromagnetic field (electromagnetic wave), having a higher propagation speed than that of an acoustic wave, for communication between an underwater vehicle and a mother vessel or the like so as to allow real-time control of the underwater vehicle and the like and further to make the communication little sensitive to noise and the like. The communication device performs wireless communication between an underwater vehicle in water and an object on land or on water, and is configured to compress data to be transmitted and transmit/receive the compressed data by the use of a low-frequency electromagnetic field.

Abstract: The present invention provides a medicament exhibiting an excellent nerve cell death inhibitory action. The present invention relates to a nerve cell death inhibitor comprising a pitavastatin and donepezil or a salt thereof in combination.

Abstract: A compound represented by the following general formula (I), wherein R1, R2, R3, R4 and R5 represent hydrogen atom, a halogen atom, a lower alkyl group and the like, R6 represents an alkyl group, a cycloalkyl group and the like, R7 and R8 represent hydrogen atom, a lower alkyl group, a (lower cycloalkyl)(lower alkyl) group and the like, R9 represents hydrogen atom, a halogen atom, a lower alkoxy group and the like, R10 and R11 represent hydrogen atom, a lower alkyl group, a lower alkoxy group, a halo(lower alkyl) group and the like, and A represents a heterocyclic ring constituted by 6 to 10 atoms, which has potent inhibitory activity on cholesterol ester transfer protein (CETP).

Abstract: A compound represented by the following general formula (I), wherein R1, R2, R3, R4 and R5 represent hydrogen atom, a halogen atom, a lower alkyl group and the like, R6 represents an alkyl group, a cycloalkyl group and the like, R7 and R8 represent hydrogen atom, a lower alkyl group, a (lower cycloalkyl)(lower alkyl) group and the like, R9 represents hydrogen atom, a halogen atom, a lower alkoxy group and the like, R10 and R11 represent hydrogen atom, a lower alkyl group, a lower alkoxy group, a halo(lower alkyl) group and the like, and A represents a heterocyclic ring constituted by 6 to 10 atoms, which has potent inhibitory activity on cholesterol ester transfer protein (CETP).

Abstract: A hypertriglyceridemia therapeutic agent made up of a synergistically effective blood-triglyceride decreasing amount of a combination of a pitavastatin and eicosapentaenoic acid (EPA), or an ester thereof.